Evidence map›Paper›PMID 42213909›Full record

ArticleJournal of chemical information and modeling2026

Contact-Network Phenotyping of the CDK Family Reveals Selective Distal C-Lobe Contact Redistribution by Modern CDK5 Inhibitors and a Quantitative Selectivity Landscape against CDK2 and CDK1.

Manal A Nael, Laxman M Alakonda, Khaled M Elokely

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Manal A NaelDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta31527, Egypt.
Laxman M AlakondaDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wyoming, 1000 E. University Avenue, Laramie, Wyoming82071, United States.ORCID 0009-0000-6749-0479
Khaled M ElokelyDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wyoming, 1000 E. University Avenue, Laramie, Wyoming82071, United States.ORCID 0000-0002-2394-021X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective inhibition of CDK5 over CDK1, CDK2, CDK4, and CDK6 remains a central medicinal-chemistry challenge because pocket-centric methods capture local similarity but not full-domain structural phenotypes. Here we introduce kinase-aware contact-network phenotyping, a calculation-light approach that combines systematic Cα contact-map comparison with automated kinase topology annotation across 30 curated CDK crystal structures spanning CDK1, CDK2, CDK3, CDK4, CD5, and CD6 with 21 pairwise comparisons. Three findings emerge. First, the apo CDK5 to selective inhibitor transition (1H4L to 7VDP) produces 33.3% ligand-adjacent gained contacts (13 of 39), compared with 2.8% (1 of 36) for the apo to nonselective transition (1H4L to 1UNL); the apo-anchored ratio of 11.9-fold quantifies the selective-specific reorganization while controlling for generic pocket-occupancy effects, with the largest distance shifts (up to 14.6 Å) concentrated in the distal C-lobe core (residues 221 to 292). Second, the DFG aspartate D144 has the most atypical contact environment in CDK5 by the Miyazawa-Jernigan knowledge-based statistical-potential

Indexed as

CDC2 Protein KinaseCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 5Protein Kinase InhibitorsHumansModels, MolecularPhenotypeProtein ConformationCDC2 Protein KinaseCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 5Protein Kinase Inhibitors

Identifiers

PMID42213909
PMCPMC13292211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.